CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 29 enrolled
Drug / intervention
LY900014 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02317575
NCT02317575Phase 1Completed
CompareCT.gov

Safety, Tolerability, Pharmacokinetics and Glucodynamics of Multiple Insulin Lispro (LY900014) Formulations

Eli Lilly and Company·interventional·Posted Dec 16, 2014·Updated May 13, 2020

In Brief

A Phase 1 clinical trial evaluating LY900014 and Insulin Lispro for Healthy Volunteers. Completed, enrolled 29 participants across 1 site.

Detailed Summary

This study evaluated four test formulations of a glucose lowering drug (LY900014) administered by injection under the skin of the abdomen. The study was conducted in healthy people to investigate how the human body handles LY900014 and the effect of LY900014 on blood sugar levels. Side effects and tolerability were documented. The study was to be conducted in two parts (Part A and Part B) to achieve its objectives. Each part of the study was to last for about 11 to 12 weeks, including screening and follow up. Screening was required within 28 days prior to entering into either study Part A or Part B. Part B was not executed because no suitable formulation was identified.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesSingapore
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 16, 2014
Enrollment StartJan 1, 2015
Primary CompletionApr 1, 2015
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.5 years ago

Interventions

LY900014biological

Administered SC

Insulin Lisprobiological

Administered SC